Remarkably, treatment with the ROS inhibitor apocynin (a NADPH oxidase inhibitor) significantly reduced the migratory and invasive capacity of U251 glioma cells under hypoxia in parallel to the pharmacologic concentration of melatonin. This evidence concerns the gene FMO5 and central nervous system cancer.